Antidepressant Suicidality Class Risk Will Be Reviewed By Advisory Committees
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA releases analysis of pediatric suicidality data for joint meeting of Psychopharmacologic Drugs and Pediatric Advisory Committees. The analysis could result in label changes for antidepressants, FDA Talk Paper says.
You may also be interested in...
Pediatric Antidepressant Safety: “Jury Is Still Out,” FDA Tells Congress
Discussion of regulatory status of antidepressant indications is almost an afterthought during Sept. 9 House hearing. FDA’s Woodcock, however, stresses that agency is not ready to rule out a role for antidepressants in children.
Pediatric Antidepressant Safety: “Jury Is Still Out,” FDA Tells Congress
Discussion of regulatory status of antidepressant indications is almost an afterthought during Sept. 9 House hearing. FDA’s Woodcock, however, stresses that agency is not ready to rule out a role for antidepressants in children.
Antidepressant Makers Expected To Testify At Sept. 9 Hearing On Trial Data Disclosure
House Commerce/Oversight Subcommittee Vice Chairman Greg Walden will oversee discussion of FDA, industry handling of data on antidepressant-related pediatric suicides.